JP2023524518A5 - - Google Patents

Info

Publication number
JP2023524518A5
JP2023524518A5 JP2022566660A JP2022566660A JP2023524518A5 JP 2023524518 A5 JP2023524518 A5 JP 2023524518A5 JP 2022566660 A JP2022566660 A JP 2022566660A JP 2022566660 A JP2022566660 A JP 2022566660A JP 2023524518 A5 JP2023524518 A5 JP 2023524518A5
Authority
JP
Japan
Prior art keywords
compound according
pharmaceutical
powder
crystalline
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022566660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524518A (ja
JP7702427B2 (ja
Filing date
Publication date
Priority claimed from GBGB2006390.5A external-priority patent/GB202006390D0/en
Application filed filed Critical
Publication of JP2023524518A publication Critical patent/JP2023524518A/ja
Publication of JP2023524518A5 publication Critical patent/JP2023524518A5/ja
Application granted granted Critical
Publication of JP7702427B2 publication Critical patent/JP7702427B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022566660A 2020-04-30 2021-04-30 炎症性腸疾患を治療するための5-クロロ-4-ヒドロキシ-1-メチル-2-オキソ-n-フェニル-キノリン-3-カルボキサミドカリウム塩 Active JP7702427B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2006390.5 2020-04-30
GBGB2006390.5A GB202006390D0 (en) 2020-04-30 2020-04-30 Novel treatments
PCT/EP2021/061464 WO2021219881A1 (en) 2020-04-30 2021-04-30 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt for treating inflammatory bowel diseases

Publications (3)

Publication Number Publication Date
JP2023524518A JP2023524518A (ja) 2023-06-12
JP2023524518A5 true JP2023524518A5 (https=) 2024-05-10
JP7702427B2 JP7702427B2 (ja) 2025-07-03

Family

ID=71080611

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022566660A Active JP7702427B2 (ja) 2020-04-30 2021-04-30 炎症性腸疾患を治療するための5-クロロ-4-ヒドロキシ-1-メチル-2-オキソ-n-フェニル-キノリン-3-カルボキサミドカリウム塩
JP2022566661A Pending JP2023524519A (ja) 2020-04-30 2021-04-30 炎症性腸疾患の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022566661A Pending JP2023524519A (ja) 2020-04-30 2021-04-30 炎症性腸疾患の治療

Country Status (9)

Country Link
US (2) US20230167064A1 (https=)
EP (2) EP4142725A1 (https=)
JP (2) JP7702427B2 (https=)
KR (2) KR20230018386A (https=)
CN (2) CN115768429B (https=)
AU (2) AU2021262514A1 (https=)
CA (2) CA3177000A1 (https=)
GB (2) GB202006390D0 (https=)
WO (2) WO2021219881A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
CN115836056A (zh) * 2020-05-21 2023-03-21 Stemsynergy疗法有限责任公司 Notch抑制剂及其用途
CN115120727B (zh) * 2022-06-16 2024-02-23 甘肃农业大学 S100a9抑制剂在制备防治c型产气荚膜梭菌感染性腹泻药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
ES2393814T3 (es) * 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
WO2012006538A1 (en) * 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2590653A4 (en) * 2010-07-09 2014-01-01 Teva Pharma 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
WO2012050500A1 (en) 2010-10-14 2012-04-19 Lars Pettersson 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
US9200046B2 (en) * 2011-06-29 2015-12-01 Cornell University Reporter system for high throughput screening of compounds and uses thereof
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments

Similar Documents

Publication Publication Date Title
JP2013237682A5 (https=)
JP2023524518A5 (https=)
HRP20120066T1 (hr) Kalijeva sol inhibitora hiv integraze
JP2012516344A5 (https=)
JP2010514807A5 (https=)
JP2010514806A5 (https=)
JP2011522827A5 (https=)
JP2023036708A5 (https=)
JP2015522616A5 (https=)
IL214086A (en) Malt salt of n- {4 - {[7,6- bis (methyllaxy) quinoline-4-yl] oxy} phenyl) - n- (4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms for cancer treatment
JP2015518885A5 (https=)
PH12020551488A1 (en) Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents
JP2023553930A5 (https=)
JP2018516883A5 (https=)
JP2022511800A5 (https=)
JP2014530818A5 (https=)
GB2605894A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt
JP2007532560A5 (https=)
JP2015537009A5 (https=)
JP2023109937A5 (https=)
JP2023027066A5 (https=)
JP2006249089A5 (https=)
JP2015522037A5 (https=)
JP2011527687A5 (https=)
CA2647346A1 (en) Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid